Turnstone Biologics is engaged in the development of medicines to treat and cure patients with solid tumors. Co. is developing a differentiated approach to tumor infiltrating lymphocyte (TIL) therapies by selecting the potent, which able to mediate an anti-tumor response and tumor-reactive T cells. Co. has initiated two Phase 1 clinical trials for its Selected TIL product candidate, TIDAL-01, for the treatment of breast cancer, colorectal cancer, uveal melanoma and other non-cutaneous and cutaneous melanomas. Co. also advances on its preclinical pipeline programs including TIDAL-02, next Selected TIL program and TIDAL-01 viral immunotherapy combination program. The TSBX YTD return is shown above.
The YTD Return on the TSBX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether TSBX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TSBX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|